Aeolus Pharmaceuticals Inc. (AOLS)
OTC PINK OTC PINK Primary Summary
AOLS Chart
Aeolus Pharmaceuticals Inc. (AOLS) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Aeolus Pharmaceuticals Inc. ever had a stock split?
Aeolus Pharmaceuticals Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Christopher Stanley CEO | OTC PINK Exchange | 00765G109 CUSIP |
| US Country | 4 Employees | - Last Dividend | 16 Jul 2004 Last Split | - IPO Date |
Overview
Aeolus Pharmaceuticals, Inc. is a pioneering biopharmaceutical company based in Mission Viejo, California, established in 1994. The company focuses on the development of a novel platform of compounds designed for applications in several critical areas: biodefense, fibrosis, oncology, infectious diseases, and central nervous system disorders. A significant aspect of Aeolus Pharmaceuticals' mission is the creation of medical countermeasures against nuclear, radiological, and chemical threats, alongside treatments for various diseases. The innovative approach centers on catalytic antioxidant compounds, providing a groundbreaking method in addressing both diseases and potential biological threats.
Products and Services
- AEOL 10150
AEOL 10150 stands at the forefront of Aeolus Pharmaceuticals' product line, having completed two Phase I clinical trials. It is primarily developed as a countermeasure against the pulmonary sub-syndrome of acute radiation syndrome, a critical focus in biodefense. Additionally, AEOL 10150 is explored for its potential application in protecting against damage from chemical vesicants and nerve agents, offering a versatile defense mechanism in chemical and radiological emergencies.
- AEOL 11114B, AEOL 11203, and AEOL 11207
These compounds are being explored by Aeolus for their potential in treating central nervous system disorders, with a particular emphasis on Parkinson's disease. Parkinson's disease, a chronic and progressive movement disorder, presents a significant challenge in medical science, and these compounds reflect Aeolus Pharmaceuticals' dedication to innovative solutions in CNS diseases.
- AEOL 20415
AEOL 20415 represents Aeolus Pharmaceuticals' venture into tackling infectious diseases. This development underscores the company's commitment to expanding its research and product offerings beyond biodefense and CNS disorders, tapping into the urgent need for new treatments in infectious diseases, a field that continues to demand innovative approaches and solutions.
